Biotie Therapies

Türkiye
Niğde, Niğde Province, Turkey, FI-20520

Company profile

Biotie Therapies company profile

Biotie is a specialized drug development company focused on central nervous system and inflammatory diseases. It has several innovative small molecule and biological drug candidates at different stages of clinical development. Biotie's products address diseases with high unmet medical need and significant market potential, including addiction and a broad range of inflammatory conditions such as rheumatoid arthritis and chronic obstructive pulmonary disease (COPD). The most advanced product, nalmefene for alcohol dependence, is currently in phase III clinical development by licensing partner H. Lundbeck A/S.

Business identity

Contact email
[email protected]
Phone number
+135822748900
Operating status
Active
Company type
For Profit
Employee range
11-50 employees
Revenue range
$0-$1M
Founded
1992-01-01, Year

Headquarters

Postal code
FI-20520
Country code
TR
Continent
Asia

Capital profile

Funding and company signals

Funding stage
M And A
Funding rounds
7
Total equity funding
$250.5M
Last funding
Post IPO Equity / $6.1M / 2015-06-01
Last equity funding
Post IPO Equity / $6.1M
Investors
1
Founders
1
Articles
14
Exited on
2015-06-11

Founders and investors

Founders

Markku Jalkanen

Investors

Aboa Venture Management